Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

[1]  田地 浩史.  Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody , 2001 .

[2]  J. Ravetch,et al.  Inhibitory pathways triggered by ITIM-containing receptors. , 1999, Advances in immunology.

[3]  M. Czuczman,et al.  Use of rituximab, the new FDA-approved antibody. , 1998, Current opinion in oncology.

[4]  D. Fearon,et al.  Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors. , 1998, Journal of immunology.

[5]  D Tripathy,et al.  Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Seto,et al.  Growth Inhibition of CD20‐positive B Lymphoma Cell Lines by IDEC‐C2B8 Anti‐CD20 Monoclonal Antibody , 1998, Japanese journal of cancer research : Gann.

[7]  L. Norton,et al.  Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. , 1998, Cancer research.

[8]  J. Ledbetter,et al.  Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. , 1998, Blood.

[9]  A. Houghton,et al.  Fc receptors are required in passive and active immunity to melanoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[10]  D. Longo,et al.  Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[11]  M. Ono,et al.  Augmented humoral and anaphylactic responses in FcγRII-deficient mice , 1996, Nature.

[12]  R. Kumar,et al.  Growth inhibition of breast cancer cell lines by combinations of anti-P185HER2 monoclonal antibody and cytokines. , 1996, Anticancer research.

[13]  S. Shire,et al.  Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. , 1995, Biochemistry.

[14]  J. Ravetch,et al.  FcR γ chain deletion results in pleiotrophic effector cell defects , 1994, Cell.

[15]  T. Waldmann.  Lymphokine receptors: a target for immunotherapy of lymphomas. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  J. Mendelsohn,et al.  Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. , 1993, Cancer research.

[17]  L. Presta,et al.  Humanization of an anti-p185HER2 antibody for human cancer therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[18]  A. Ullrich,et al.  p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor , 1989, Molecular and cellular biology.

[19]  J. Mendelsohn,et al.  Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes. , 1986, Cancer research.

[20]  M. Winget,et al.  p 185 HER 2 Monoclonal Antibody Has An ( iproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor , 2022 .